Cassava Sciences (NASDAQ:SAVA) has appointed Joseph Hulihan as chief medical officer.
He will devote approximately half of his professional time to Cassava, advising on the development of simufilam, the company’s investigational candidate for the treatment of Tuberous Sclerosis Complex-related epilepsy.
Hulihan brings over 25 years of experience in neurology and epilepsy drug development, having held senior roles at Marinus Pharmaceuticals and Janssen Pharmaceutical Companies of Johnson & Johnson previously.
